Swiss Re Expands Longevity Reinsurance Business with Major US Market Entry

Swiss Re enters the US longevity reinsurance market with a $2B Athene deal, leveraging 20 years of global expertise as the business becomes a core revenue driver.

Swiss Re has successfully executed its first longevity reinsurance transaction in the United States, marking a significant geographic expansion for the reinsurer. The $2 billion deal with US insurer Athene represents a strategic move into one of the world's largest markets for such financial instruments, built upon two decades of international experience in this sector.

Strategic Focus and Portfolio Refinement

This US debut coincides with a broader strategic sharpening of focus within Swiss Re. Ivan Gonzalez, the company's CEO, emphasized a strategy of concentrating on core strengths rather than maintaining a presence in every market segment. This approach is evident in the Corporate Solutions unit, where Trade Credit insurance is becoming a priority. The strategic intent is further underscored by the planned acquisition of QBE's Australian Trade and Credit unit.

Simultaneously, Swiss Re's latest "sigma" report highlights emerging liability risks, specifically analyzing manufacturers of highly processed foods. This research comes as government agencies increasingly file lawsuits seeking public cost reimbursements related to health impacts.

A Growing Core Business

Longevity reinsurance, which involves managing the financial risk of people living longer than expected, is now a substantial part of Swiss Re's portfolio. It is far from a niche offering. In the 2025 financial year, this segment contributed 17% of the total insurance revenue for the Life & Health Reinsurance division, making it the unit's second-largest business line.

The company's history in this field spans approximately 20 years. Prior to the US entry, Swiss Re had secured pension benefits exceeding $50 billion for more than one million retirees, exclusively in markets including the United Kingdom, the Netherlands, Singapore, and Australia.

Market Reaction and Future Indicators

Investors responded positively to the strategic developments. Swiss Re's share price is currently trading approximately 6% above its 50-day moving average. With a Relative Strength Index (RSI) reading of 43.6, the stock is neither in overbought territory nor showing clear technical weakness. However, it remains about 11% below its 52-week high of €166.25, which was recorded in November 2025.

The market will be looking for early signs of the US market entry's impact when Swiss Re reports its first-quarter 2026 results on May 7, 2026. These figures will provide the next concrete data point on the transaction's operational contribution.